promote the healing of wounds to the upper respiratory tract **[and/or the]** <u>or</u> ear, **[characterised in that the preparation contains]** <u>comprising</u> at least one **[of said agents]** <u>agent</u> combined with a particulate carrier.

A'cont.

2. (Amended) The preparation **[process]** of claim 1, <u>wherein</u> **[characterised in that]** said particulate carrier comprises at least one of a liposome preparation, a microsphere preparation, a nanoparticle preparation, a Large Porous Particle preparation, or a laser-pulse polymer coated molecule preparation.

3. (Amended) The preparation **[process]** according to claim 1 **[or 2]**, <u>wherein</u> **[characterised in that]** at least the greatest part of said agent is encapsulated inside the carrier, **[especially]** <u>comprising</u> a liposome or microsphere carrier.

4. (Amended) The preparation **[process]** of **[any one of claims 1 to 3]** <u>claim 1, wherein</u> **[characterised in that the]** <u>the</u> anti-inflammatory agent is an antiseptic agent, an antibiotic, a corticosteroid, or a wound-healing promoting agent.

5. (Amended) The **[process]** <u>preparation</u> of **[any one of claims 1 to 4]** <u>claim 1,</u> **[characterised in that]** <u>wherein</u> the antiseptic agent is selected from oxygen-<u>releasing compounds,</u> **[and]** halogen-releasing compounds, metal compounds, such as silver <u>compounds,</u> **[and]** mercury compounds; organic disinfectants, **[including inter alia]** formaldehyde-releasing

compounds, alcohols, phenols, including **alkylphenols[, and]** arylphenols as well as halogenated phenols, quinolines and acridines, hexahydropyrimidines, quaternary ammonium compounds and iminium salts, and guanidines.

A' cont.

6. (Amended) The **[process] preparation** according to claim 5, **wherein [characterised in that]** the antiseptic agent is selected from the group comprising metal compounds, such as mercury compounds, phenol derivatives, such as thymol, eugenol, **[and]** hexachlorophene, iodine and iodine complexes.

7. (Amended) The **[process] preparation** according to claim 6, **wherein [characterised in that]** the antiseptic agent is povidone iodine.

8. (Amended) The **[process] preparation** according to **[any one of claims 1 to 7] claim1, wherein [characterised in that]** the wound-healing promoting agent is selected from agents promoting granulation and epithelization such as dexpanthenol, allantoines, azulenes, tannines, **or** compounds from the vitamin B series**[, or similarly acting agents]**.

9. (Amended) The **[process] preparation** according to **[any one of the preceding claims] claim 1, wherein [characterised in that]** the preparation contains at least one antiseptic and at least one wound-healing promoting agent.

A'cont.

10. (Amended) The **[process]** **preparation** according to **[any one of the preceding claims]** **claim 1**, **wherein** **[characterised in that the carrier particles]** **the particulate carrier**, **[especially liposomes, have]** **has** a substantially uniform size in the range between about 20 **nm** and about 20,000 nm**[, preferably in the range between about 50 and about 4,000 nm, more preferably between 500 and 2,500 nm and especially preferably a uniform size of about 1,000 nm]** diameter.

11. (Amended) The **[process]** **preparation** according to **[any one of the preceding claims]** **claim 1**, **wherein** **[characterised in that]** the **particulate** carrier**[, especially liposome,]** preparation releases the agent over an extended time period**[, preferably an extended time period of several hours duration]**.

12. (Amended) The **[process]** **preparation** according to claim 11, **wherein** **[characterised in that]** the **particulate** carrier**[, especially liposome,]** preparation releases the agent at approximately the same release rate over the release time period.

13. (Amended) The **[process]** **preparation** according to **[any one of the preceding claims]** **claim 1**, **wherein** **[characterised in that]** the preparation **[additionally]** comprises at least one **[anaesthetically]** **anesthetically** active agent.

14. (Amended) The **[process]** **preparation** according to **[any one of the preceding claims]**

claim 1, wherein [characterised in that] the preparation contains additives and adjuvants such as conserving agents, antioxidants and consistency-forming additives.

A' cont.

15. (Amended) The [process] preparation according to [any one of claims 1 to 14] claim 1, the preparation being in the form of a solution or dispersion comprising the active-agent loaded carrier, [especially in the form of liposomes, preferably] in the form of a liquid pharmaceutical preparation.

16. (Amended) The [process] preparation according to [one of claims 1 to 14] claim 1, the preparation being in the form of a hydrophilic or amphiphilic cream, comprising the carrier and agent formulation in a hydrophilic or amphiphilic cream base, or in the form of a pharmaceutical O/W or W/O lotion.

17. (Amended) The [process] preparation according to [any one of claims 1 to 14] claim 1, the preparation being in the form of a pharmaceutical ointment, containing the carrier and agent or agents in a pharmaceutical ointment base.

18. (Amended) The [process] preparation according to [any one of claims 1 to 14] claim 1, the preparation being in the form of a pharmaceutical gel, [especially] a non-alcoholic hydrogel containing the carrier and agents or agents in a pharmaceutically acceptable hydrogel basis.

A'cont.

19. (Amended) The **[process] preparation** according to **[any one of claims 1 to 14] claim 1**, the preparation being in the form of a spray containing the carrier and agent in a pharmaceutically acceptable sprayable solid or liquid formulation.

20. (Amended) The **[process] preparation** according to **[any one of the preceding claims] claim 1**, the preparation being in the form of a pharmaceutical solution or dispersion formulation, which comprises:

(a) liposomes compromising a pharmaceutically acceptable liposome membrane forming substance; and

(b) a 0.1 to 2% PVP iodine solution **comprising [**at approximately 10% available iodine in the PVP iodine complex**]** at least most of which is encapsulated by said liposome membranes,

wherein the liposomes are of substantially uniform size between about 50 nm and about 4,000 nm, and, in case, the formulation additionally comprises customary additives, adjuvants and auxiliary substances of a pharmaceutical solution or dispersion formulation.

21. (Amended) The **[process] preparation** according to claim 20, **wherein [characterised in that]** the liposomes are of substantially uniform size, with diameters at around 1,000 nm, and the formulation is a gel.

22. (Amended) The **[process] preparation** according to **[any one of claims 1 to 21] claim 1**,

A' cont.

wherein the preparation is suited for the treatment of infectious diseases or alleviation of diseases such as HIV infections which are accompanied by opportunistic infections **[or]** **and diseases of** a suppressed immune system.

23. (Amended) The **[process]** **preparation** according to **[any one of claims 1 to 21]** **claim 1**, wherein the preparation is suited for the treatment of acute **laryngopharyngitis**, **[and/or]** chronic laryngopharyngitis, angina **[and/or]** **or** rhinitis.

24. (Amended) The **[process]** **preparation** according to **[any one of claims 1 to 21]** **claim 1**, wherein the preparation is suited for functional and cosmetic tissue **[remodelling]** **remodeling** and repair treatments.

Sub B3

25. (Amended) A method of preventing or treating infections **[and/or]** of functional and cosmetic tissue **[remodelling]** **remodeling** and repair, of the human or animal upper respiratory tract **[and/or]** **or** ear, by applying to said tract **[and/or]** **or** ear, a pharmaceutical preparation, comprising at least one anti-inflammatory, **[especially]** antiseptic agent **[and/or]** **or** wound-healing promoting agent, said at least one agent being combined with a particulate carrier in **[said]** **the** preparation.

A2

27. (Amended) The method of claim 25, wherein at least the greatest part of **[agent is]** **the agents are** encapsulated inside the carrier, **[especially]** **comprising** a liposome or microsphere

carrier.

A2 cont.

28. (Amended) The method of claim 25, wherein the anti-inflammatory agent is selected from **the group consisting of** antiseptic agents, antibiotics, corticosteroids and wound-healing promoting agents.

Sub B4

29. (Amended) The method of claim 25, wherein the antiseptic agent is selected from **the group consisting of** oxygen-**releasing compounds** and halogen-releasing compounds; metal compounds, such as silver **compounds** and mercury compounds; organic disinfectants including **[inter alia]** formaldehyde-releasing compounds, alcohols, phenols including alkylphenols **[-and]** arylphenols**, [as well as]** halogenated phenols, quinolines**, [and]** acridines, hexahydropyrimidines, quaternary ammonium compounds**, [and]** iminium salts, and guanidines.

Sub B5

30. (Amended) The method of claim 25, wherein the antiseptic agent **[is selected from the group comprising]** **comprises** metal compounds such as mercury compounds, phenol derivatives**,** such as thymol, eugenol and hexachlorophene, iodine and iodine complexes.

A3

Sub B6

32. (Amended) The method of claim 25, wherein the wound-healing promoting agent **[is selected from]** **comprises** agents promoting granulation and epithelization such as dexpanthenol, allantoines, azulenes, tannines**[,]** **or** compounds from the vitamin B series**[, or similarly acting agents]**.

A4

Sub B7

34. (Amended) The method of claim 25, wherein the carrier particles**[, especially liposomes, have]** **has** a substantially uniform size in the range between about 20 **nm** and about 20,000 nm**[, preferably in the range between about 50 and about 4,000 nm, more preferably between 500 and 2,500 nm and especially preferably a uniform size of about 1,000 nm]** diameter.

35. (Amended) The method of claim 25, wherein the carrier **[, especially liposome, preparation]** releases the agent over an extended time period**[, preferably an extended time period of several hours duration]**.

36. (Amended) The method of claim 25, wherein that the carrier**[, especially liposome,]** preparation releases the agent at approximately the same release rate over the release time period.

37. (Amended) The method of claim 25, wherein the preparation additionally comprises at least one **[anaesthetically]** **anesthetically** active agent.

A5

Sub B8

39. (Amended) The method of claim 25, **wherein** the preparation **[being]** **is** in the form of a solution or dispersion comprising the active-agent loaded carrier **[, especially in the form of liposomes, preferably]** in the form of a liquid pharmaceutical preparation.

40. (Amended) The method of claim 25, **wherein** the preparation **[being]** **is** in the form of a

Sub B cont. A5 cont

hydrophilic or amphiphilic cream, comprising the carrier and agent formulation in a hydrophilic or amphiphilic cream base, or in the form of a pharmaceutical O/W or W/O lotion.

41. (Amended) The method of claim 25, **wherein** the preparation **[being]** **is** in the form of a pharmaceutical ointment, containing the carrier and agent or agents in a pharmaceutical ointment base.

42. (Amended) The method of claim 25, **wherein** the preparation **[being]** **is** in the form of a pharmaceutical gel, **[especially]** a non-alcoholic hydrogel containing the carrier and agent or agents in a pharmaceutically acceptable hydrogel basis.

Sub B9

43. (Amended) The method of claim 25, **wherein** the preparation **[being]** **is** in the form of a spray containing the carrier and agent in a pharmaceutically acceptable sprayable solid or liquid formulation.

44. (Amended) The method of claim 25, **wherein** the preparation **[being]** **is** in the form of a pharmaceutical solution or dispersion formulation, which comprises:

(a) liposomes compromising a pharmaceutically acceptable liposome membrane forming substance; and

(b) a 0.1 to 2% PVP iodine solution [(]at approximately 10% available iodine in the PVP iodine complex[)] at least most of which is encapsulated by said liposome membranes,

A5 cont'd

228.1006

Sub B9 cont'd

wherein the liposomes are of substantially uniform size between about 50 nm and about 4,000 nm, and, in case, the formulation additionally 3w customary additives, adjuvants and auxiliary substances of a pharmaceutical solution or dispersion formulation.

A6

46. The method of claim 25, wherein the preparation **[is suited for the]** **comprises a** treatment of infectious diseases or alleviation of diseases such as HIV infections which are accompanied by opportunistic infections **[or]** **and diseases of** a suppressed immune system.

47. (Amended) The method of claim 25, wherein the preparation is suited for the treatment of laryngopharyngitis, angina [and/or] **or** rhinitis.

Please **add** new claims 48-53 as follows:

A7

--48. (New) The preparation according to claim 10, wherein the particulate carrier, has a substantially uniform size in the range between about 50 nm and about 4,000 nm diameter.--

--49. (New) The preparation according to claim 10, wherein the particulate carrier, has a substantially uniform size in the range between 500 nm and 2,500 nm diameter.--

--50. (New) The preparation according to claim 10, wherein the particulate carrier, has a substantially uniform size of about 1,000 nm diameter.--

Sub B10

--51. (New) The method of claim 25, wherein the carrier particles comprise a substantially uniform size in the range between about 50 nm and about 4,000 nm diameter.--